IMMUNIC, INC. (IMUX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. This filer's financial year end could not be read from its revenue history, so quarters are labelled by the calendar. Amounts in USD.

Revenue Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Gross Profit Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Annual

-150M -100M -50M 0 50M 100M 150M 2012: -9.6M 2013: -31.4M 2014: -50.3M 2015: -52.1M 2016: -41.3M 2017: -52.7M 2018: -12M 2019: -37M 2020: -49M 2021: -91.7M 2022: -119.5M 2023: -99.2M 2024: -98.1M 2025: -103.2M 2013 2015 2017 2019 2021 2023 2025

Net Income Annual

-150M -100M -50M 0 50M 100M 150M 2012: -6.7M 2013: -32.7M 2014: -47.7M 2015: -52M 2016: -41M 2017: -52.1M 2018: -11.5M 2019: -34.9M 2020: -44M 2021: -92.9M 2022: -120.4M 2023: -93.6M 2024: -100.5M 2025: -97.2M 2013 2015 2017 2019 2021 2023 2025

Cost of Revenue Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Annual

-90M -60M -30M 0 30M 60M 90M 2012: -9.2M 2013: -28.6M 2014: -40.8M 2015: -50M 2016: -35.8M 2017: -40.4M 2018: -9.7M 2019: -28.5M 2020: -46.1M 2021: -83.2M 2022: -65.1M 2023: -70.8M 2024: -84.8M 2025: -85.8M 2013 2015 2017 2019 2021 2023 2025

Free Cash Flow Annual

-90M -60M -30M 0 30M 60M 90M 2012: -9.5M 2013: -30.1M 2014: -42.2M 2015: -52.3M 2016: -36.3M 2017: -41.1M 2018: -9.8M 2019: -28.6M 2020: -46.3M 2021: -83.3M 2022: -65.3M 2023: -71.2M 2024: -85M 2025: -86M 2013 2015 2017 2019 2021 2023 2025

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 60M 120M 180M 2020: 15.7M 2021: 23.7M 2022: 31.8M 2023: 44.3M 2024: 100.2M 2025: 155.7M 2020 2021 2022 2023 2024 2025

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-90.00 -60.00 -30.00 0.00 30.00 60.00 90.00 Q4 '13: -75.03 Q1 '14: -77.41 Q2 '14: -63.99 Q3 '14: -48.27 Q4 '14: -26.58 Q1 '15: -2.71 Q2 '15: -2.43 Q3 '15: -2.35 Q4 '15: -2.10 Q1 '16: -1.79 Q2 '16: -1.46 Q3 '16: -1.27 Q4 '16: -1.30 Q1 '17: -1.38 Q2 '17: -1.37 Q3 '17: -1.35 Q4 '17: -1.33 Q1 '20: -3.88 Q2 '20: -3.26 Q3 '20: -3.14 Q4 '20: -2.92 Q1 '21: -3.76 Q2 '21: -3.68 Q3 '21: -3.74 Q4 '21: -4.02 Q1 '22: -3.13 Q2 '22: -3.03 Q3 '22: -2.96 Q4 '22: -3.77 Q1 '23: -3.61 Q2 '23: -3.43 Q3 '23: -3.25 Q4 '23: -2.11 Q1 '24: -1.83 Q2 '24: -1.50 Q3 '24: -1.23 Q4 '24: -1.00 Q1 '25: -3.21 Q2 '25: -5.03 Q3 '25: -4.92 Q4 '25: -0.62 Q1 '26: 0.81 Q2 '26: 2.04 Q4 '13 Q2 '15 Q4 '16 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.